These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 24481846)

  • 1. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure.
    Oka T; Akazawa H; Naito AT; Komuro I
    Circ Res; 2014 Jan; 114(3):565-71. PubMed ID: 24481846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Fas in the progression of ischemic heart failure: prohypertrophy or proapoptosis.
    Feng QZ; Zhao YS; Abdelwahid E
    Coron Artery Dis; 2008 Nov; 19(7):527-34. PubMed ID: 18923250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart.
    Hilfiker-Kleiner D; Hilfiker A; Kaminski K; Schaefer A; Park JK; Michel K; Quint A; Yaniv M; Weitzman JB; Drexler H
    Circulation; 2005 Sep; 112(10):1470-7. PubMed ID: 16129800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload.
    Li G; Xie J; Chen J; Li R; Wu H; Zhang X; Chen Q; Gu R; Xu B
    Cardiovasc Pathol; 2017; 28():74-79. PubMed ID: 28395201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of hypertrophic growth from changes in myocyte contractile function.
    Harding SE; Del Monte F
    J Card Fail; 2002 Dec; 8(6 Suppl):S415-20. PubMed ID: 12555154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
    McMullen JR; Jennings GL
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):255-62. PubMed ID: 17324134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
    Diwan A; Dorn GW
    Physiology (Bethesda); 2007 Feb; 22():56-64. PubMed ID: 17289931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
    J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [P53 and its role in the development of heart failure].
    Sano M; Komuro I
    Nihon Rinsho; 2008 May; 66(5):1013-21. PubMed ID: 18464525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure.
    Wang J; Xu N; Feng X; Hou N; Zhang J; Cheng X; Chen Y; Zhang Y; Yang X
    Circ Res; 2005 Oct; 97(8):821-8. PubMed ID: 16151019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy.
    Sakamoto M; Minamino T; Toko H; Kayama Y; Zou Y; Sano M; Takaki E; Aoyagi T; Tojo K; Tajima N; Nakai A; Aburatani H; Komuro I
    Circ Res; 2006 Dec; 99(12):1411-8. PubMed ID: 17095722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway.
    Shiojima I; Walsh K
    Genes Dev; 2006 Dec; 20(24):3347-65. PubMed ID: 17182864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.
    Tham YK; Bernardo BC; Ooi JY; Weeks KL; McMullen JR
    Arch Toxicol; 2015 Sep; 89(9):1401-38. PubMed ID: 25708889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice.
    Yang J; Mou Y; Wu T; Ye Y; Jiang JC; Zhao CZ; Zhu HH; Du CQ; Zhou L; Hu SJ
    Cardiovasc Res; 2013 Mar; 97(3):490-9. PubMed ID: 23180723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
    Balakumar P; Jagadeesh G
    Pharmacol Res; 2010 Nov; 62(5):365-83. PubMed ID: 20643208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.
    Sano M; Minamino T; Toko H; Miyauchi H; Orimo M; Qin Y; Akazawa H; Tateno K; Kayama Y; Harada M; Shimizu I; Asahara T; Hamada H; Tomita S; Molkentin JD; Zou Y; Komuro I
    Nature; 2007 Mar; 446(7134):444-8. PubMed ID: 17334357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac hypertrophy and failure in hypertension.
    Johnson DB; Dell'Italia LJ
    Curr Opin Nephrol Hypertens; 1996 Mar; 5(2):186-91. PubMed ID: 8744544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF; Xavier-Neto J; Dalla Costa AP; Consonni SR; Antunes JE; Rocco SA; Pereira MB; Judice CC; Strauss B; Joazeiro PP; Matos-Souza JR; Franchini KG
    J Mol Cell Cardiol; 2012 Feb; 52(2):493-501. PubMed ID: 22056317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.
    Shiojima I; Sato K; Izumiya Y; Schiekofer S; Ito M; Liao R; Colucci WS; Walsh K
    J Clin Invest; 2005 Aug; 115(8):2108-18. PubMed ID: 16075055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.